ENTRADA THERAPEUTICS INC
TRDANASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $4.11 β $16.45
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 38.9M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $25M
- Last Q Revenue
- $905,000
- P/E Ratio
- β
- P/S Ratio
- 38.8x
- EPS (TTM)
- $-3.97
- Dividend Yield
- β
- Dilution (1yr)
- β3.9%
ENTRADA THERAPEUTICS INC
TRDAAbout ENTRADA THERAPEUTICS INC
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.